Skip to main content
Swing Capital

Brooks Laboratories Ltd

NSE: BROOKS BSE: 533543Pharma

Incorporated in 2002, Brooks Laboratories Ltd is a pharmaceutical company working on contract basis catering to the critical care segment[1]

₹45.4
52W: ₹36.3 — ₹166
PE 20.4 · Book ₹40.7 · +12% vs book
Market Cap₹134 Cr
Stock P/E20.4Price to Earnings
ROCE4.29%Return on Capital
ROE3.28%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Company is almost debt free.
  • +Stock is trading at 1.11 times its book value

Weaknesses

  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of 3.45% over past five years.
  • −Tax rate seems low
  • −Company has a low return on equity of -1.68% over last 3 years.
  • −Contingent liabilities of Rs.75.7 Cr.
  • −Promoter holding has decreased over last 3 years: -13.8%

Shareholding Pattern

Promoters52.62%
FIIs0.17%
DIIs10.38%
Public36.84%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters63.59%63.59%59.06%▼4.552.62%▼6.452.62%52.62%52.62%52.62%
FIIs0%0.02%▲0.00.01%▼0.00.05%▲0.00%▼0.10.01%▲0.00.09%▲0.10.17%▲0.1
DIIs3.86%3.86%3.86%10.38%▲6.510.38%10.38%10.38%10.38%
Public32.55%32.53%▼0.037.08%▲4.536.95%▼0.137%▲0.037%36.91%▼0.136.84%▼0.1

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales24.3221.7517.7217.9320.7920.5223.3225.5123.4516.57
Expenses22.620.6617.3417.6519.2818.9521.7422.3920.9315.84
Operating Profit1.721.090.380.281.511.571.583.122.520.73
OPM %7.07%5.01%2.14%1.56%7.26%7.65%6.78%12.23%10.75%4.41%
Net Profit1.180.580.3-0.210.960.941.372.652.240.3
EPS ₹0.450.220.11-0.080.370.360.470.90.760.1

AI Insights

Revenue Trend

TTM revenue at ₹88.85Cr, up 7.6% YoY. OPM at 8.95%.

Debt Position

Borrowings at ₹7.83Cr. Debt-to-equity ratio: 0.09x. Healthy balance sheet.

Capex Cycle

CWIP at ₹0.92Cr (7% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 10.38% (+10.38pp change). FIIs: 0.17% (+0.17pp change). Promoters hold 52.62%.

Margin & Efficiency

ROCE declining from 7.03% (Mar 2014) to 4.29% (Mar 2025). Working capital days: 43.28.

Valuation

PE 20.4x with 4.29% ROCE. Price is 12% above book value of ₹40.7. Dividend yield: 0%.

Recent Announcements